Table 1.
Baseline demographic and clinical characteristics
| Characteristics | Total (N=81) |
|---|---|
| Median age (Q1–Q3), years | 60 (52–69) |
| Male, n (%) | 54 (66.7) |
| Prior nephrectomy, n (%) | 68 (83.9) |
| Metastatic at diagnosis, n (%) | 28 (34.6) |
| Stage, n (%) | |
| III | 4 (4.9) |
| IV | 71 (87.6) |
| ECOG PS, n (%) | |
| 0 | 6 (7.4) |
| 1 | 62 (76.5) |
| ≥2 | 13 (16.0) |
| MSKCC risk group, n (%) | |
| Favorable (0 risk factor) | 15 (18.5) |
| Intermediate (1–2 risk factors) | 47 (58.0) |
| Poor (≥3 risk factors) | 10 (12.3) |
| Number of metastatic sites, n (%) | |
| 1 | 29 (35.8) |
| 2 | 23 (28.4) |
| ≥3 | 29 (35.7) |
| Site of metastases, n (%) | |
| Lung | 63 (77.8) |
| Lymph nodes | 32 (39.5) |
| Bone | 19 (23.5) |
| Liver | 14 (17.3) |
| Brain | 4 (4.9) |
Notes: Data are expressed as n (%). Missing data: MSKCC (n=9). Risk factors are low serum hemoglobin level, elevated corrected serum calcium level, elevated serum lactate dehydrogenase level, a poor performance status (ECOG ≥2 or Karnosfky >80%) and an interval of <1 year between diagnosis and treatment.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; MSKCC, Memorial Sloan-Kettering Cancer Center.